Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier

被引:663
作者
Gilgun-Sherki, Y
Melamed, E
Offen, D [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Dept Neurol, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr, IL-69978 Tel Aviv, Israel
关键词
neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; antioxidants; free radicals; blood brain barrier;
D O I
10.1016/S0028-3908(01)00019-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oxidative stress (OS) has been implicated in the pathophysiology of many neurological, particularly neurodegenerative diseases. OS can cause cellular damage and subsequent cell death because the reactive oxygen species (ROS) oxidize vital cellular components such as lipids, proteins, and DNA. Moreover, the brain is exposed throughout life to excitatory amino acids (such as glutamate), whose metabolism produces ROS, thereby promoting excitotoxicity. Antioxidant defense mechanisms include removal of O-2, scavenging of reactive oxygen/nitrogen species or their precursors, inhibition of ROS formation, binding of metal ions needed for the catalysis of ROS generation and up-regulation of endogenous antioxidant defenses. However, since our endogenous antioxidant defenses are not always completely effective, and since exposure to damaging environmental factors is increasing, it seems reasonable to propose that exogenous antioxidants could be very effective in diminishing the cumulative effects of oxidative damage. Antioxidants of widely varying chemical structures have been investigated as potential therapeutic agents. However, the therapeutic use of most of these compounds is limited since they do not cross the blood brain barrier (BBB). Although a few of them have shown limited efficiency in animal models or in small clinical studies, none of the currently available antioxidants have proven efficacious in a large-scale controlled study. Therefore, any novel antioxidant molecules designed as potential neuroprotective treatment in acute or chronic neurological disorders should have the mandatory prerequisite that they can cross the BBB alter systemic administration. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:959 / 975
页数:17
相关论文
共 149 条
[31]  
*DATATOP, 1993, NEW ENGLJAND J MED, V328, P176
[32]  
DEKUMAR A, 1988, TOXICOL LETT, V44, P47
[33]  
DERIJK MC, 1997, ARCH NEUROL-CHICAGO, V54, P1762
[34]   NIGRAL DOPAMINERGIC CELL LOSS IN VITAMIN-E-DEFICIENT RATS [J].
DEXTER, DT ;
NANAYAKKARA, I ;
GOSSSAMPSON, MA ;
MULLER, DPR ;
HARDING, AE ;
MARSDEN, CD ;
JENNER, P .
NEUROREPORT, 1994, 5 (14) :1773-1776
[35]  
DEXTER DT, 1992, ANN NEUROL, V32, P94
[36]   Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids [J].
Do, TQ ;
Shultz, JR ;
Clarke, CF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7534-7539
[37]  
Doctrow S R, 1997, Adv Pharmacol, V38, P247
[38]   NMDA RECEPTORS ACTIVATE THE ARACHIDONIC-ACID CASCADE SYSTEM IN STRIATAL NEURONS [J].
DUMUIS, A ;
SEBBEN, M ;
HAYNES, L ;
PIN, JP ;
BOCKAERT, J .
NATURE, 1988, 336 (6194) :68-70
[39]   Oxidative stress and antioxidant therapy in Parkinson's disease [J].
Ebadi, M ;
Srinivasan, SK ;
Baxi, MD .
PROGRESS IN NEUROBIOLOGY, 1996, 48 (01) :1-19
[40]   BIOCHEMICAL, PHYSIOLOGICAL AND MEDICAL ASPECTS OF UBIQUINONE FUNCTION [J].
ERNSTER, L ;
DALLNER, G .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1995, 1271 (01) :195-204